NCT02626312 2025-10-14
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
9 trialsNCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03278925 2024-08-02
Defined Green Tea Catechin Extract in Preventing Liver Cancer in Participants With Cirrhosis
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT03895112 2023-02-10
MPN-RC 118 AVID200 in Myelofibrosis
Icahn School of Medicine at Mount Sinai
Phase 1 Completed
NCT02151864 2019-03-05
LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
University of California, San Diego
Phase 1 Completed
NCT01956864 2018-02-01
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
Johns Hopkins University
Phase 1 Withdrawn
NCT00706576 2017-08-02
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
University of Missouri-Columbia
Phase 1 Completed
NCT00802555 2012-07-12
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed